Zhong, Dafang

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

Zhang, J., Cao, J., Li, J., Zhang, Y., Chen, Z., Peng, W., Sun, S., Zhao, N., Wang, J., Zhong, D., et al. (2014) · Journal of Hematology & Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 40

Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins

Liu, X., Feng, D., Zheng, M., Cui, Y., & Zhong, D. (2020) · Drug Metabolism and Pharmacokinetics

Protein Interaction Studies and Fluorescence AnalysisPharmacogenetics and Drug Metabolism

Cited by 32

Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin

Wu, Y., Chen, L., Chen, J., Xue, H., He, Q., Zhong, D., & Diao, X. (2023) · Drug Metabolism and Disposition

Protein Interaction Studies and Fluorescence AnalysisPharmacogenetics and Drug Metabolism

Cited by 21

Predicting Food–Drug Interactions between Piperine and CYP3A4 Substrate Drugs Using PBPK Modeling

Lin, F., Hu, Y., Zhang, Y., Zhao, L., Zhong, D., & Liu, J. (2024) · International Journal of Molecular Sciences

Piperaceae Chemical and Biological StudiesPharmacogenetics and Drug Metabolism

Cited by 20